Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis — Emilio Portaccio (2022) | RDL Network
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis
Article 2022 en
Authors
EP
Emilio Portaccio
MF
Mattia Fonderico
PI
Pietro Iaffaldano
Abstract
1 min read
Results of this comparative effectiveness research study suggest that inflammation also occurs in patients with PPMS, may contribute to long-term disability, and may be associated with a reduced risk of becoming wheelchair dependent by current licensed DMTs.
Massimo Filippi, Maria Pia Amato, Diego Centonze, Paolo Gallo, Claudio Gasperini, Matilde Inglese, Francesco Patti, Carlo Pozzilli, Paolo Preziosa, María Trojano
Nicolás Fissolo, Pascal Benkert, Jaume Sastre‐Garriga, Neus Mongay‐Ochoa, Andreu Vilaseca-Jolonch, Sara Llufriú, Yolanda Blanco, Harald Hegen, Klaus Berek, Francisco Pérez‐Miralles, Konrad Rejdak, Luisa María Villar, Enric Monreal, Roberto Álvarez‐Lafuente, O. Soylu, Ahmed Abdelhak, Franziska Bachhuber, Hayrettin Tumani, Sergio Martínez‐Yélamos, Antonio Sánchez, Antonio Garcı́a-Merino, Lucía Gutiérrez, Tamara Castillo‐Triviño, Jan Lycke, Igal Rosenstein, Roberto Furlan, Massimo Filippi, Nieves Téllez, Lluís Ramió‐Torrentà, Jan D. Lünemann, Heinz Wiendl, Sara Eichau,
Majid Pahlevan Kakhki, Chiara Starvaggi Cucuzza, Antonino Giordano, Tejaswi V. S. Badam, Pernilla Strid, Klementy Shchetynsky, Adil Harroud, Alexandra Gyllenberg, Yun Liu, Sanjaykumar V. Boddul, Tojo James, Melissa Sorosina, Massimo Filippi, Federica Esposito, Fredrik Wermeling, Mika Gustafsson, Patrizia Casaccia, Ingrid Kockum, Jan Hillert, Tomas Olsson, Lara Kular, Maja Jagodic
Discussion(0)
No comments yet. Be the first to comment.